TipRanks
Immunovant (DE:4YB)
STUTTGART:4YB
Germany Market
4YB
Immunovant
RESEARCH TOOLSreports

Immunovant (4YB) Income Statement

0 Followers

Immunovant Income Statement

Last quarter (Q1 2027), Immunovant's total revenue was $7.09M, an increase of Infinity% from the same quarter last year. In Q1, Immunovant's net income was $-153.22M. See Immunovant’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 26Mar 25Mar 24Mar 23Mar 22
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ -409.00K$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 532.90M$ 438.15M$ 270.21M$ 208.28M$ 156.03M
Depreciation and Amortization
$ 409.00K$ 377.00K$ 231.00K$ 193.00K$ 126.00K
EBITDA
$ -504.98M$ -412.57M$ -258.54M$ -198.28M$ -156.69M
Operating Income
$ -532.90M$ -438.15M$ -270.21M$ -208.28M$ -156.03M
Other Income/Expenses
$ 27.51M$ 25.20M$ 11.44M$ -2.67M$ -781.00K
Pretax Income
$ -505.39M$ -412.95M$ -258.77M$ -210.95M$ -156.81M
Net Income
$ -505.61M$ -413.84M$ -259.34M$ -210.96M$ -156.73M
Per Share Metrics
Basic EPS
$ -2.77$ -2.73$ -1.88$ -1.71$ -1.43
Diluted EPS
$ -2.77$ -2.73$ -1.88$ -1.71$ -1.43
Weighted Average Shares Outstanding
 182.42M 151.57M 138.10M 123.08M 109.68M
Weighted Average Shares Outstanding (Diluted)
 182.42M 151.57M 138.10M 123.08M 109.68M
Currency in USD

Immunovant Earnings and Revenue History